CU23175A1 - Formulacion liposomica de propionato de clobetasol - Google Patents

Formulacion liposomica de propionato de clobetasol

Info

Publication number
CU23175A1
CU23175A1 CU20000171A CU20000171A CU23175A1 CU 23175 A1 CU23175 A1 CU 23175A1 CU 20000171 A CU20000171 A CU 20000171A CU 20000171 A CU20000171 A CU 20000171A CU 23175 A1 CU23175 A1 CU 23175A1
Authority
CU
Cuba
Prior art keywords
clobetasol propionate
active ingredient
liposomes
formulation
liposomic
Prior art date
Application number
CU20000171A
Other languages
English (en)
Inventor
Gonzalez Ignacio Her Hernandez
Gonzalez Aimee Roche Gon Roche
Gutierrez Xiomara Perez Perez
Cortada Dinorah Granda Granda
Diduk Natalia Albert Albertova
Martin-Viana Nilia De La P Paz
Leon Ladyth De La Carid Garcia
Original Assignee
Ct De Investigacion Y Desarrol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Investigacion Y Desarrol filed Critical Ct De Investigacion Y Desarrol
Priority to CU20000171A priority Critical patent/CU23175A1/es
Priority to DK01953764T priority patent/DK1360958T3/da
Priority to HK05103910.6A priority patent/HK1071070B/xx
Priority to BR0112553-2A priority patent/BR0112553A/pt
Priority to AU7625401A priority patent/AU7625401A/xx
Priority to AU2001276254A priority patent/AU2001276254B2/en
Priority to ES01953764T priority patent/ES2272508T3/es
Priority to CA002416731A priority patent/CA2416731C/en
Priority to PCT/CU2001/000005 priority patent/WO2002007702A2/es
Priority to MXPA03000207A priority patent/MXPA03000207A/es
Priority to AT01953764T priority patent/ATE339188T1/de
Priority to CNB018128955A priority patent/CN100346773C/zh
Priority to EP01953764A priority patent/EP1360958B1/en
Priority to DE60123132T priority patent/DE60123132T2/de
Publication of CU23175A1 publication Critical patent/CU23175A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con una formulacion liposomica de propionato de clobetasol para uso topico para el tratamiento de enfermedades de la piel como dermatitis atopica y la psoriasis con excelente aspecto organolÉptico, muy buen efecto terapÉutico y favorable distribucion en el estrato corneo. Los liposomas incluyen el propionato de clobetasol como principio activo en bajas dosis. Estos liposomas son preferiblemente vesículas estables y multilamelares con un tamano medio entre 2000 - 5000 nm. La cantidad de principio activo es preferiblemente entre 0.02 y 0.025 %. La forma farmacÉutica del producto es preferiblemente jalea.
CU20000171A 2000-07-17 2000-07-17 Formulacion liposomica de propionato de clobetasol CU23175A1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU20000171A CU23175A1 (es) 2000-07-17 2000-07-17 Formulacion liposomica de propionato de clobetasol
DK01953764T DK1360958T3 (da) 2000-07-17 2001-07-17 Liposomformulering af clobetasolpropionat
HK05103910.6A HK1071070B (en) 2000-07-17 2001-07-17 Liposomic formulation of clobetasol propionate
BR0112553-2A BR0112553A (pt) 2000-07-17 2001-07-17 Formulação lipossÈmica de propionato de clobetasol para aplicação tópica
AU7625401A AU7625401A (en) 2000-07-17 2001-07-17 Liposomic formulation of clobetasol propionate
AU2001276254A AU2001276254B2 (en) 2000-07-17 2001-07-17 Liposomic formulation of clobetasol propionate
ES01953764T ES2272508T3 (es) 2000-07-17 2001-07-17 Formulacion liposomica de propionato de clobetasol.
CA002416731A CA2416731C (en) 2000-07-17 2001-07-17 Liposomal formulation of clobetasol propionate
PCT/CU2001/000005 WO2002007702A2 (es) 2000-07-17 2001-07-17 Formulación liposómica de propionato de clobetasol
MXPA03000207A MXPA03000207A (es) 2000-07-17 2001-07-17 Formulacion liposomica de propionato de clobetasol.
AT01953764T ATE339188T1 (de) 2000-07-17 2001-07-17 Liposomenformulierung mit clobetasol propionate
CNB018128955A CN100346773C (zh) 2000-07-17 2001-07-17 丙酸氯倍他索的脂质体制剂
EP01953764A EP1360958B1 (en) 2000-07-17 2001-07-17 Liposomic formulation of clobetasol propionate
DE60123132T DE60123132T2 (de) 2000-07-17 2001-07-17 Liposomenformulierung mit clobetasol propionate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20000171A CU23175A1 (es) 2000-07-17 2000-07-17 Formulacion liposomica de propionato de clobetasol

Publications (1)

Publication Number Publication Date
CU23175A1 true CU23175A1 (es) 2006-09-22

Family

ID=40134847

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000171A CU23175A1 (es) 2000-07-17 2000-07-17 Formulacion liposomica de propionato de clobetasol

Country Status (12)

Country Link
EP (1) EP1360958B1 (es)
CN (1) CN100346773C (es)
AT (1) ATE339188T1 (es)
AU (2) AU2001276254B2 (es)
BR (1) BR0112553A (es)
CA (1) CA2416731C (es)
CU (1) CU23175A1 (es)
DE (1) DE60123132T2 (es)
DK (1) DK1360958T3 (es)
ES (1) ES2272508T3 (es)
MX (1) MXPA03000207A (es)
WO (1) WO2002007702A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60028411T2 (de) 1999-10-13 2007-01-04 Johns Hopkins University School Of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
BR0117063A (pt) * 2001-07-02 2004-07-27 Sinan Tas Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
WO2017037663A1 (en) 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
AU661754B2 (en) * 1992-02-12 1995-08-03 Janssen - Cilag - S.p.a. Liposomal itraconazole formulations

Also Published As

Publication number Publication date
AU7625401A (en) 2002-02-05
DK1360958T3 (da) 2007-01-29
CN1547465A (zh) 2004-11-17
HK1071070A1 (zh) 2005-07-08
WO2002007702A3 (es) 2003-07-31
ES2272508T3 (es) 2007-05-01
CA2416731C (en) 2009-12-15
EP1360958A2 (en) 2003-11-12
DE60123132D1 (de) 2006-10-26
EP1360958B1 (en) 2006-09-13
CN100346773C (zh) 2007-11-07
MXPA03000207A (es) 2004-09-13
CA2416731A1 (en) 2003-01-16
AU2001276254B2 (en) 2006-07-13
ATE339188T1 (de) 2006-10-15
WO2002007702A2 (es) 2002-01-31
DE60123132T2 (de) 2007-04-12
BR0112553A (pt) 2003-06-24

Similar Documents

Publication Publication Date Title
US20240115707A1 (en) Dna repair composition
US8367100B2 (en) Preparation and use of sleeve and micro-encapsulated topical analgesic patch for treating pain
AU743528B2 (en) Cosmetic compositions
ES2599973T3 (es) Una formulación tópica de propionato de clobetasol de nivel bajo para tratar trastornos de la membrana mucosa y de la piel
CA2196780A1 (en) A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
CA1261757A (en) Compositions for treating acne vulgaris and methods of making and using same
EP1138323A3 (en) Resveratrol for the treatment of exfoliative eczema, acne or psoriasis
NO962972D0 (no) Preparat for perkutan absorpsjon
CA2175472A1 (en) Propylene glycol stearate vesicles
JP2007508243A (ja) 両親媒性コポリマーゲル化剤を含む泡坦体
DE69530368D1 (de) Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung
US20060088497A1 (en) Topical skin care composition
AU2003233921A1 (en) Atomizable liposomes and their use for the pulmonary administration of active substances
DE60123132D1 (de) Liposomenformulierung mit clobetasol propionate
HUT57590A (en) Process for producing liposome compositions comprisings antiandrogenic active ingredient
Korting et al. Topical liposome drugs to come: what the patent literature tells us: a review
NZ504274A (en) Topical water-in-oil anaesthetic formulation for use in pain management
US20230355493A1 (en) Topical composition
WO2001041706A2 (en) Lipid nanotubules for topical delivery
KR100206721B1 (ko) 화장용 방취 및 항균 조성물
ATE337774T1 (de) Treibgasfreie sprayzubereitungen
JPH04338319A (ja) 養毛化粧料
EP0815842A3 (en) Medicaments and cosmetics comprising zizyphus-spina-christi extracts
Millward Skincare Benefits of Phosphatidylcholine
FREE Tugain 10 for Hair Loss and Beard Growth

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)